Fidelity SPDR Advertisement
Home > Boards > Free Zone > User's Groups > Mohacsy's Safe Portfolio Member Forum

Orphan Drug Status doesn't assure FDA approval of

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
n4807g Member Profile
Member Level 
Followed By 32
Posts 27,420
Boards Moderated 0
Alias Born 07/08/03
160x600 placeholder
Roche Hit By Failure Of Cancer Drug Trial
Roche said a late-stage study of its breast cancer drug Kadcyla failed to yield superior results to an existing treatment, damaging the outlook for stronger sales in one of its key drug markets.
More Top Equities Stories Of The Day
Deezer Names New CEO Before Full U.S. Launch
Whistleblowers Score a Big Payday -- Update
Mobile's Rise Poses a Riddle for Banks
AT&T Boosts Dividend
U.S. Hot Stocks: Hot Stocks to Watch
Brazilian Shares Rise, Led by Rossi Residencial; Real Weakens Slightly
Oracle Beats Street View for First Time in a Year
Alstom CEO Expects to Settle DOJ Bribery Allegations Very Soon
n4807g Member Level  Monday, 04/23/12 12:16:00 PM
Re: FullBoogie post# 60301
Post # of 69122 
Orphan Drug Status doesn't assure FDA approval of the compound being evaluated, it confers certain marketing advantages and tax credits should the drug be approved.

Like most small biotechs CYTR will succeed or fail on the technology they employ. In CYTR's case the delivery system. The near term future of INNO-206 will be clear when they report interim findings of their ongoing 2b trial.

Like all biotechs this is a speculative investment, but I've watched many companies with similar strategies do well. The preliminary data look promising (no guarantee) but as I said in my previous post Abraxane uses Albumin as the entry vehicle in tumors and CYTR uses the same concept.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist